Beware copycat probes after Sanofi generics case
This article was originally published in Scrip
This week's €40.6 million fine against Sanofi could presage further investigations into the legality of techniques used by pharmaceutical companies to protect their franchises from generic competition. However, with the lack of previous cases addressing the specific abuses brought to light in the Sanofi case, the limits of acceptable practice may be hard to define, and the need for companies to tread carefully is complicated by the difficulty in pinning down future interpretations of legality.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.